A life sciences company does not usually struggle because it lacks policies. It struggles because AI moves faster than validation, supplier review, clinical governance, and privacy controls. That is why an effective AI governance example for life sciences needs to show more than principles. It needs to show how decisions are made, who owns them, and what evidence exists when regulators, partners, or internal audit ask questions.
In life sciences, AI rarely sits in a low-risk corner of the business. It appears in pharmacovigilance workflows, medical information support, quality management, R&D analytics, commercial forecasting, and document review. Some use cases may look administrative at first, but the underlying data, downstream impact, and regulated context can quickly raise the stakes.
What a practical AI governance example for life sciences looks like
Consider a mid-sized life sciences company operating in the UK and EU, with clinical development activity, a growing medical affairs function, and outsourced technology support. The business wants to deploy an AI tool to assist with adverse event case intake and triage. The tool does not make final safety decisions, but it summarises reports, extracts relevant fields, and routes cases for human review.
On paper, this sounds manageable. In practice, it touches personal data, special category data, regulated safety obligations, vendor risk, recordkeeping, and model performance oversight. A useful governance model therefore starts with one basic rule: no AI system enters production without crossing three coordinated reviews - legal, privacy, and technical operations.
That three-team model matters because each function sees a different part of the risk. Legal and compliance teams assess regulatory exposure, contractual controls, and accountability. Privacy teams assess data flows, lawful handling, retention, transfers, transparency, and impact assessment requirements. Technical operations assess system architecture, access controls, testing, logging, change management, and integration with existing controls. Without all three, governance becomes partial and difficult to defend.
The operating model behind the example
In this example, the company creates a formal AI intake process. The business owner cannot simply buy or activate a tool. Instead, they submit the proposed use case into an internal AI system register with a short description of purpose, users, data involved, supplier details, outputs, and whether the tool influences regulated decisions.
That register becomes the control point for governance. It distinguishes between enterprise AI tools, departmental pilots, embedded third-party AI functionality, and higher-impact use cases connected to patient safety, product quality, or regulated submissions. This sounds administrative, but it solves a common problem in life sciences: AI appears through procurement, software updates, and local team experimentation long before central governance catches up.
The first review in the workflow is risk classification. The company asks five practical questions. Does the system process personal or health data? Does it influence regulated activities? Does it generate content or recommendations that staff might rely on? Is there a third-party provider involved? Can the model change over time through updates or retraining? The answers determine whether the use case can follow a light review path or requires full assessment and senior approval.
For the adverse event triage tool, the answer is clear. The use case is not treated as a general productivity tool. It is classified as high-governance due to health data, safety process involvement, and dependency on a vendor model.
Controls applied to the life sciences use case
Once the use case is classified, the organisation moves into documented controls. This is where many governance frameworks become too vague. In a life sciences environment, each control should map to an operational owner and a record of completion.
The privacy team completes an impact assessment covering the categories of personal data, data sources, access permissions, retention, international transfers, and the specific risk of inaccurate summarisation. In a pharmacovigilance context, a poor summary is not just a quality issue. It may lead to delayed escalation or incomplete case handling. The governance response therefore needs to treat privacy, quality, and safety as connected rather than separate workstreams.
The legal and compliance review focuses on supplier due diligence, defined use limitations, confidentiality terms, audit rights, subcontractor visibility, and obligations around incident notification and model changes. If the vendor can materially alter the model or hosting arrangement without notice, governance is weak from the outset.
Technical operations then test the system in a controlled environment. They review role-based access, logging, prompt handling, output traceability, integration points, and whether users can distinguish machine-generated content from validated case information. They also define what the system must not do. In this case, the tool may draft summaries and suggest routing categories, but it cannot close a case, suppress escalation, or replace qualified human review.
That boundary is one of the most important controls in the entire example. In life sciences, governance often depends less on banning AI and more on placing it inside clear operational limits.
Human oversight is not a slogan
Many organisations state that humans remain in the loop. That is not enough. In a credible AI governance example for life sciences, human oversight is defined with precision.
For the adverse event use case, the company documents who reviews outputs, what competence they need, when they must override the system, and how overrides are recorded. It sets a quality threshold for extraction accuracy and requires periodic sampling against manually reviewed cases. If error rates increase, or if certain report types perform poorly, the system is paused or restricted until remediation is completed.
This is also where governance meets training. Users are not merely shown how to operate the tool. They are trained on approved use, prohibited use, escalation routes, and the specific failure modes relevant to safety reporting. A user who assumes the AI summary is complete introduces a different risk from a user who treats the output as a draft requiring verification. Governance has to shape that behaviour.
Vendor governance is central in life sciences
A large share of AI risk in life sciences sits with third-party providers, especially where the model is embedded in a broader software platform. Organisations often know the application vendor but not the underlying model dependencies, support arrangements, or data handling chain.
A strong governance model therefore includes AI-specific vendor assessment. The company reviews where data is processed, whether customer data is used for model training, what explainability is available, how performance is monitored, what security controls exist, and how updates are communicated. If the provider cannot answer basic governance questions, the issue is not only contractual. It is operational. The organisation may lack enough visibility to use the system responsibly in a regulated environment.
This is where execution-focused support matters. Governance in life sciences cannot rely on a policy sitting in a shared drive. It needs workflows, decision logs, supplier review steps, approval gates, and assigned accountability across teams. Organisations working across jurisdictions also need a structure that can absorb overlapping requirements from privacy law, sector regulation, and AI-specific obligations without creating duplicate processes.
Documentation that stands up to scrutiny
The most useful output of governance is not the policy itself. It is the evidence trail. In this example, the company maintains an AI record containing the use case description, classification outcome, approval decision, impact assessments, vendor review, testing evidence, oversight plan, training record, and change log.
That record supports internal audit, quality review, board reporting, and external scrutiny. It also makes repeatability possible. When the next AI use case appears in medical information or quality documentation, the organisation is not starting from zero.
This is one reason mature organisations are aligning AI governance with broader management systems rather than treating it as a standalone legal exercise. AI system registries, documented approval workflows, periodic reviews, and cross-functional ownership allow businesses to scale governance with more control. For internationally active organisations, this becomes even more relevant when obligations span multiple territories and regulatory frameworks.
Where this example often goes wrong
The common failure points are predictable. Teams deploy tools before they are registered. Procurement reviews the supplier but not the model behaviour. Privacy teams assess data protection but do not connect the analysis to safety or quality impact. Technical testing focuses on access security but not output reliability. Senior stakeholders approve a pilot without defining exit criteria, performance thresholds, or accountability for ongoing review.
None of these failures are unusual. They happen because AI governance is often assigned to one function when it actually requires coordinated execution. A practical model needs legal, privacy, and technical operations working together, with business owners accountable for real-world use.
For life sciences organisations, that coordination is not optional. The regulatory environment is too interconnected, the data too sensitive, and the operational consequences too significant.
A good governance framework should make AI easier to use safely, not harder to deploy altogether. If the business can classify a use case, assess the real risks, place controls around it, document decisions, and monitor performance over time, AI becomes manageable within a regulated operating model. That is the standard worth aiming for - not perfect certainty, but clear control that can hold up when the questions become serious.
Formiti's life sciences AI governance and DPO services give regulated organisations a repeatable operating model across the UK, EU and beyond.